The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
Medicines Manufacturing Industry Partnership (MMIP) represents the voice of medicines manufacturers in the UK. It was established jointly by Government and the biopharmaceutical industry in 2014 to ensure that the UK is recognised by the global medicines industry as a world-class, advanced centre for medicines manufacturing.
The UK's medicine industry is one of the country's leading manufacturing sectors, with exports worth over £20bn. The Partnership wants to ensure that the UK continues to be an attractive place for this high-value industry to secure exports, provide high skilled job opportunities and contribute to solving the country's productivity puzzle.
MMIP is supported by the Association of the British Pharmaceutical Industry (ABPI), the BioIndustry Association (BIA) and Knowledge Transfer Network (KTN), and includes leadership from AstraZeneca, Eisai, FUJIFILM Diosynth Biotechnologies, GlaxoSmithKline, Pfizer and ReNeuron. The Chair of MMIP is Andy Evans, Head of Macclesfield Site at AstraZeneca.
1. At £154,000 the direct gross value added (GVA) per employee of manufacture of pharmaceutical products is the highest in Europe, 40% higher than Germany and Italy, 50% higher than Spain andalmost twice the level achieved in France.
Source: PwC, 'The Economic contribution of the UK Life Sciences industry ', March 2017